Senores Pharmaceuticals reported a 25% surge in consolidated revenue to Rs 192.33 crore for Q2 FY27. Net profit climbed 22% YoY to Rs 36.60 crore. Management targets 30-40% revenue growth for the full fiscal year, backed by a portfolio that has nearly doubled in regulated markets.
Senores Pharmaceuticals Q2 Profit Grows 22% To Rs 36.6 Crore
Revenue rose 25% to Rs 192.33 crore; Net Profit reached Rs 36.60 crore.
Reader Takeaway: Strong double-digit growth in top and bottom lines offset by rising operational costs in new subsidiaries.
What just happened
Senores Pharmaceuticals posted its ninth consecutive quarter of double-digit growth. For the quarter ended September 2026, the company reported consolidated revenue of Rs 192.33 crore, a 25% jump from the previous year. Net profit stood at Rs 36.60 crore, compared to Rs 30.12 crore in the same period last year. EBITDA rose to Rs 58 crore, marking a 38% year-on-year increase.
Why this matters
The company is scaling its global presence, with its regulated market portfolio growing from 34 ANDAs in September 2025 to 64 ANDAs by September 2026. This expansion forms the core of management’s aggressive FY27 guidance, which targets a 30-40% revenue increase and 50-60% PAT growth. The operational efficiency remains a focus as the firm balances current expansion with future scaling.
Risks to watch
Investors should monitor the operational burn rate associated with subsidiaries Zoraya and Amerisyn. These units have incurred initial set-up costs without yet providing significant revenue contributions. Management expects these investments to contribute to growth from FY28 onwards. Additionally, the appointment of M/s Talati and Talati LLP as a joint statutory auditor is pending shareholder approval.
Context metrics
Cash generated from operations improved to Rs 38 crore in H1 FY27, up from Rs 31 crore in H1 FY26. The firm maintains a strong pipeline visibility, aiming for a 20-25% annual growth rate for the two fiscal years following FY27.